In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Nektar Therapeutics (NKTR), with a price target of $35.00. The company’s shares closed last Thursday at $19.88.
According to TipRanks.com, Yang is ranked 0 out of 5 stars with an average return of -11.1% and a 31.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nektar Therapeutics with a $27.67 average price target, representing a 39.4% upside. In a report issued on May 5, Canaccord Genuity also maintained a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.85 and a one-year low of $13.64. Currently, Nektar Therapeutics has an average volume of 1.51M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
